Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD? - 09/08/11
, STEPHEN V. FARAONE, Ph.D., JOSEPH BIEDERMAN, Ph.D., MARC LERNER, M.D., KIMBERLY M. COOPER, M.S., BRENDA ZIMMERMAN, M.S.ON BEHALF OF THE CONCERTA STUDY GROUP
ABSTRACT |
Objective |
To investigate whether prolonged therapy with a long-acting stimulant affects growth in children with attention-deficit/hyperactivity disorder (ADHD).
Method |
One hundred seventy-eight children ages 6 to 13 years received OROS methylphenidate (OROS MPH, CONCERTA) for at least 21 months. Height and weight were measured monthly during the first year and every 3 months thereafter.
Results |
At baseline, subjects were approximately the expected height for their age and somewhat heavier than expected. Subjects gained height steadily throughout the study and were on average 0.23 cm less than expected at month 21. Weight did not increase and BMI decreased slightly in the first 4 months. Thereafter, weight Z score and BMI Z score remained relatively constant and children were on average 1.23 kg less than expected at month 21. Previous stimulant therapy tended to be associated with a smaller decrease in Z score during the study compared with no previous stimulant therapy. Drug holidays did not significantly affect growth.
Conclusions |
The effects of prolonged OROS MPH therapy on growth were clinically insignificant and limited to slight decreases in weight during the first months of therapy. Drug holidays did not reduce any impact on growth and are thus of questionable utility for limiting potential effects of treatment on growth. J. Am. Acad. Child Adolesc. Psychiatry, 2006;45(5):000-000.
Le texte complet de cet article est disponible en PDF.Key Words : growth, height, weight, attention-deficit/hyperactivity disorder, methylphenidate, OROS methylphenidate, CONCERTA
Plan
| This study was supported by McNeil Consumer and Specialty Pharmaceuticals. Disclosure: Dr. Spencer receives research support from Shire Laboratories, Eli Lilly, GlaxoSmithKline, Pfizer, McNeil Pharmaceutical, Novartis, and the National Institute of Mental Health. He is on the speakers’ bureaus of GlaxoSmithKline, Eli Lilly, Novartis, Wyeth Ayerst, Shire, and McNeil Pharmaceutical, and is on the advisory boards of Shire, Eli Lilly, GlaxoSmithKline, Pfizer, McNeil Pharmaceutical, and Novartis. Dr. Faraone has received research funding and consulting fees from the study sponsor, McNeil Consumer & Specialty Pharmaceuticals. Dr. Biederman receives research support from Shire, Eli Lilly, Pfizer, McNeil Pharmaceutical, Abbott Laboratories, Bristol-Myers Squibb, New River Pharmaceuticals, Cephalon, Janssen Pharmaceutical, NeuroSearch, Stanley Medical Institute, the Lilly Foundation, and the Prechter Foundation. He is on the speakers’ bureaus of Shire, Eli Lilly, McNeil Pharmaceutical, Cephalon, and UCB Pharma, and is on the advisory boards of Eli Lilly, Shire, McNeil Pharmaceutical, Janssen, Novartis, and Cephalon. Dr. Lerner receives grant and/or research support from Shire, McNeil Consumer & Specialty Pharmaceuticals, Cephalon, Novartis, and UCB. He is a consultant for Shire and McNeil Consumer & Specialty Pharmaceuticals, and is on the speakerapos;s bureaus of Shire, McNeil, Consumer & Specialty Pharmaceuticals, Novartis, and UCB. Ms. Zimmerman and Ms. Cooper are employees of McNeil Consumer & Specialty Pharmaceuticals. |
Vol 45 - N° 5
P. 527-537 - mai 2006 Retour au numéro
Article précédent
- Comparative Effects of Methylphenidate and Mixed Salts Amphetamine on Height and Weight in Children With Attention-Deficit/Hyperactivity Disorder
- STEVEN R. PLISZKA, THOMAS L. MATTHEWS, KENNETH J. BRASLOW, MELISSA A. WATSON
- Test-Retest Reliability of the Preschool Age Psychiatric Assessment (PAPA)
- HELEN LINK EGGER, ALAATTIN ERKANLI, GORDON KEELER, EDWARD POTTS, BARBARA KEITH WALTER, ADRIAN ANGOLD
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?